Follow
International Journal of Current Microbiology and Applied Sciences (IJCMAS)
IJCMAS is now DOI (CrossRef) registered Research Journal. The DOIs are assigned to all published IJCMAS Articles.
Index Copernicus ICI Journals Master List 2017 - IJCMAS--ICV 2017: 100.00 For more details click here
National Academy of Agricultural Sciences (NAAS) : NAAS Score: *5.38 (2019) [Effective from January 1, 2019]For more details click here

Login as a Reviewer

Indexed in



National Academy of Agricultural Sciences (NAAS)
NAAS Score: *5.38 (2019)
[Effective from January 1, 2019]
For more details click here

ICV 2017: 100.00
Index Copernicus ICI Journals Master List 2017 - IJCMAS--ICV 2017: 100.00
For more details click here

See Guidelines to Authors
Current Issues

Original Research Articles

PRINT ISSN : 2319-7692
Online ISSN : 2319-7706
Issues : 12 per year
Publisher : Excellent Publishers
Email : editorijcmas@gmail.com / submit@ijcmas.com
Editor-in-chief: Dr.M.Prakash
Index Copernicus ICV 2017: 100.00
NAAS RATING 2018: 5.38

Int.J.Curr.Microbiol.App.Sci.2018.7(8): 4340-4348
DOI: https://doi.org/10.20546/ijcmas.2018.708.455


A Single Center Observational Study to Evaluate Epidemiology and Susceptibility Patterns to Antimicrobial Agents at a Tertiary Care Hospital in India
Pritam Jagansing Pardeshi
Consultant Microbiologist, Bhatia Hospital, Mumbai, India
*Corresponding author
Abstract:

The continuous change in microbial sensitivity to antimicrobial agents necessitates to have knowhow of local susceptibility patterns so as to help clinicians choose the right pathogen specific antimicrobial therapies. This retrospective study assessed the phenotypic characteristics of pathogens isolated from different clinical specimens and their susceptibility to some of second line of antibiotics like Ceftriaxone-Sulbactam-EDTA (CSE-1034), Meropenem, Piperacillin-Tazobactam (Pip/Taz) and Cefaperazone-Sulbactam used in our hospital settings. A total of 241 Gram-negative isolates from 600 patients treated for various bacterial infections during May 2017 to December 2017 were included in the study. Four antimicrobial agents (Ceftriaxone-sulbactam-EDTA, Meropenem, Piperacillin-Tazobactam and Cefaperazone-Sulbactam) have been used and extended spectrum β-lactamases (ESBL) and metallo β-lactamases (MBL) production was confirmed by double-disk synergy test. Of the 241Gram negative isolates obtained from 600 patients, 168 isolates were from Inpatient department (IPD) and 73 from Intensive care unit (ICU) patients. In IPD, the isolates were predominantly obtained from urine (52.4%) and wound (22.0%) whereas in ICU patients, the predominant specimens were respiratory (39.7%) and urine (36.9%). E. coli was detected in 41.5% of clinical specimens followed by K. pneumoniae (21.9%) and P. aeruginosa (15.4%). 65.6% of the isolates were reported beta-lactamase producers with 34.4% (83) as ESBL producers, 0.8% (2) as MBL producers and 30.3% (73) as ESBL+MBL producers. CSE-1034 had the greatest activity against both ESBL and ESBL+MBL producing isolates. ESBL isolates were sensitive to CSE-1034 (93.9%), Meropenem (83.1%), Cefaperazone-Sulbactam (61.4%) and Pip/Taz (51.8%). The susceptibility rates of ESBL/MBL producing isolates were CSE-1034 (75.2%), Cefaperazone-Sulbactam (8.2%), Meropenem (5.5%), and Pip-Taz (2.7%). This retrospective data suggests that CSE-1034 can be considered as an important therapeutic option for the treatment of infections caused by both ESBL and ESBL+MBL producing Gram-negative isolates


Keywords: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii
Download this article as Download

How to cite this article:

Pritam Jagansing Pardeshi. 2018. A Single Center Observational Study to Evaluate Epidemiology and Susceptibility Patterns to Antimicrobial Agents at a Tertiary Care Hospital in India.Int.J.Curr.Microbiol.App.Sci. 7(8): 4340-4348. doi: https://doi.org/10.20546/ijcmas.2018.708.455